{"entity":{"id":"lunit","kind":"company","name":"Lunit","aka":[],"tldr":"Korean AI company spanning mammography reading (INSIGHT MMG), breast-density risk (Volpara), and AI pathology for immunotherapy biomarkers.","summary":"21 studies at ECR 2026 covering INSIGHT MMG, Scorecard (ex-Volpara density), and INSIGHT CXR; a large Dutch randomised trial using Scorecard showed supplemental MRI in dense breasts reduced advanced cancer incidence. Lunit SCOPE pathology AI partnered with Labcorp and CellCarta (2025-26) for companion diagnostics.","asOf":"2026-09-04","links":[{"label":"ECR 2026","url":"https://www.prnewswire.com/news-releases/lunit-to-be-featured-in-21-ai-imaging-studies-on-breast-cancer-and-lung-disease-at-ecr-2026-302703651.html"}],"tags":[],"related":[],"cancers":["breast-hr-positive","tnbc","nsclc"],"sections":["ai-computation","imaging","early-detection"],"technologies":["radiology-ai-screening","digital-pathology-ai","mammography"],"targets":[],"drugs":[],"companies":["volpara-health"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Seoul","country":"KR","companyType":"ai-software","website":"https://www.lunit.io","ticker":"328130.KQ","investors":[],"funding":[]},"route":"/companies/lunit/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"},{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"},{"id":"imaging","kind":"section","name":"Imaging","route":"/fronts/imaging/"}],"technology":[{"id":"radiology-ai-screening","kind":"technology","name":"AI in radiology","route":"/technologies/radiology-ai-screening/"},{"id":"digital-pathology-ai","kind":"technology","name":"Digital pathology & AI","route":"/technologies/digital-pathology-ai/"},{"id":"mammography","kind":"technology","name":"Mammography & tomosynthesis","route":"/technologies/mammography/"}],"company":[{"id":"volpara-health","kind":"company","name":"Volpara Health","route":"/companies/volpara-health/"}],"bottleneck":[{"id":"b-ai-validation","kind":"bottleneck","name":"AI that is built but not validated or deployed","route":"/bottlenecks/b-ai-validation/"},{"id":"b-workforce","kind":"bottleneck","name":"Not enough oncologists, nurses, pathologists, physicists","route":"/bottlenecks/b-workforce/"}],"idea":[{"id":"idea-prev-ldct-ai-negative-triage","kind":"idea","name":"AI clears the normal lung screening scans so radiologists read only the suspicious ones","route":"/ideas/idea-prev-ldct-ai-negative-triage/"},{"id":"idea-tr1-ai-central-imaging-reads","kind":"idea","name":"AI-assisted central imaging reads to cut endpoint cost and variability","route":"/ideas/idea-tr1-ai-central-imaging-reads/"},{"id":"idea-acc-ai-first-pathology-common-cases","kind":"idea","name":"AI-first reading for high-volume common cancer diagnoses, pathologist for the exceptions","route":"/ideas/idea-acc-ai-first-pathology-common-cases/"},{"id":"idea-tr2-radiomics-ibsi-mandate","kind":"idea","name":"No clinical claims for imaging-derived biomarkers without phantom and standards compliance","route":"/ideas/idea-tr2-radiomics-ibsi-mandate/"},{"id":"idea-prev-mammography-ai-stepped-wedge","kind":"idea","name":"Roll out AI-supported mammography nationally as a stepped-wedge trial","route":"/ideas/idea-prev-mammography-ai-stepped-wedge/"},{"id":"idea-prev-ai-mammogram-risk-intervals","kind":"idea","name":"Set each woman's mammogram interval from her last mammogram, using AI risk","route":"/ideas/idea-prev-ai-mammogram-risk-intervals/"},{"id":"idea-bio2-spatial-signature-cdx","kind":"idea","name":"Turn the map of immune cells inside a tumour into a standardised test","route":"/ideas/idea-bio2-spatial-signature-cdx/"}],"drug":[{"id":"lunit-insight-mmg","kind":"drug","name":"Lunit INSIGHT MMG","route":"/drugs/lunit-insight-mmg/"}],"trial":[{"id":"screentrustcad","kind":"trial","name":"ScreenTrustCAD","route":"/trials/screentrustcad/"}],"paper":[{"id":"paper-screentrustcad-dembrower-lancet-digit-health-2023","kind":"paper","name":"Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study (ScreenTrustCAD)","route":"/key-papers/paper-screentrustcad-dembrower-lancet-digit-health-2023/"}]}}